This clinical study treated all patients tested

A study published Sunday, June 5 in the New England Journal of Medicine has a 100% success rate in a clinical trial of a rectal cancer drug. Results that show real hope.

This is remarkable progress. A clinical trial of a drug to treat colorectal cancer is raising real hope for patients. The success rate is 100%. This new drug was tested on 12 patients, as reported by the New England Journal of Medicine. The American researchers at Memorial Sloan Kettering Cancer Center, who are behind this study, are very surprised by the results: “I believe this is the first time in the history of cancer.”says dr Luis Diaz.

“Great optimism”

Colorectal cancer, which includes the rectum, is the second most common cancer in women and the third most common in men. In this study, the researchers specifically looked at one of its forms, which is associated with a genetic mutation called MMrD or “Mismatch Repair Deficit”. These tumors are usually less sensitive to chemotherapy and radiotherapy.

Until now, this type of treatment has not really been part of routine colorectal cancer care. how it happens Dostarlimab is mainly used to treat endometrial cancer. But the results of this new research work “are a source of great optimism”after Dr. Sanoff.

Colon cancer: what is this miracle cure?

In particular, it is a drug that works “Not by attacking the cancer itself directly, but by taking care of it that a person’s immune system does most of the work, explains Dr. Hanna Sanoff from the University of North Carolina. Dostarlimab was administered to the 12 patients every three weeks for a period of six months. This treatment was originally supposed to be followed by standard chemotherapy and surgery, but six months after stopping the drug, the cancer was gone. Today, two years after the study, the participants have not relapsed, had surgery, or required chemotherapy or radiation therapy. A real feat on the field!

Patients with colorectal cancer soon cured? The results of this study are remarkable

Leave a Comment